Shitara and Xu Discuss Potential FDA Approval of Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

Rui-Hua Xu, MD, PhD, and Kohei Shitara, MD, expand on the advantages of targeting CLDN18.2 with zolbetuximab in gastric/GEJ adenocarcinoma and key efficacy data from the GLOW and SPOTLIGHT trials in support of zolbetuximab’s potential FDA approval.

Related Keywords

Japan ,China ,Guangzhou ,Guangdong ,Kohei Shitara ,Rui Hua Xu ,Department Of Gastrointestinal Oncology ,Sun Yat Sen University Cancer Center ,National Cancer Center Hospital ,Gastrointestinal Oncology ,National Cancer Center Hospital East ,Kashiwa City ,Zolbetuximabs Potential Fda Approval ,Targeting Cldn18 2 With Zolbetuximab In Gastric Gej Adenocarcinoma ,Efficacy Data From The Glow And Spotlight Trials ,